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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERCardiohepatic Interactions in HF 2397
Marc D. Samsky, Chetan B. Patel, Tracy A. DeWald, Alastair D. Smith, G. Michael Felker,
Joseph G. Rogers, Adrian F. Hernandez
In this paper, Samsky and colleagues review the effects of heart failure (HF) on hepatic
function. They discuss the clinical presentation, histological ﬁndings, and biochemical
proﬁles of patients presenting with acute and chronic liver injury secondary to HF. In
addition, the use of liver function tests as prognostic markers, implication of liver injury on
drug metabolism and the management of liver injury from acute and chronic HF are
summarized.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYThe TWENTE 2-Year Outcome After 12 Months of DAPT 2406Kenneth Tandjung, Hanim Sen, Ming Kai Lam, Mounir W. Z. Basalus, J. (Hans) W. Louwerenburg,
Martin G. Stoel, K. Gert van Houwelingen, Frits H. A. F. de Man, Gerard C. M. Linssen,
Salah A. M. Saïd, Mark B. Nienhuis, Marije M. Löwik, Patrick M. J. Verhorst,
Job van der Palen, Clemens von Birgelen
Tandjung and colleagues report on the 2-year outcome of patients (n ¼ 1,391) implanted
randomly with second-generation drug-eluting stents, Resolute zotarolimus-eluting stent
(ZES) versus Xience V everolimus-eluting stent (EES). Patients had complex lesions and
there was strict discontinuation of dual antiplatelet therapy at 12 months. The primary
endpoint of target vessel failure and composite of cardiac death, target vessel-related
myocardial infarction, and target vessel revascularization did not differ between ZES and
EES (10.8% vs. 11.6; p ¼ 0.65). The 2-year deﬁnite or probable stent thrombosis rates were
1.2% and 1.4% (p ¼ 0.63), respectively. Very late deﬁnite or probable stent thrombosis
occurred in 2 patients of each arm. The authors conclude that the Resolute ZES and Xience
V EES showed similar results with regards to safety and efﬁcacy.(continued on page A-14)
JUNE 18, 2013 (continued) A-14INTERVENTIONAL CARDIOLOGY2-Year Zilver PTX Results for Femoropoliteal Lesions 2417
Michael D. Dake, Gary M. Ansel, Michael R. Jaff, Takao Ohki, Richard R. Saxon, H. Bob Smouse,
Scott A. Snyder, Erin E. O’Leary, Gunnar Tepe, Dierk Scheinert, Thomas Zeller,
on behalf of the Zilver PTX Investigators
This study evaluated the 2-year safety and effectiveness of paclitaxel-coated drug-eluting
stents (DES) to percutaneous transluminal angioplasty (PTA) and provisional bare-metal
stent (BMS) in patients with superﬁcial femoral artery disease. Patients were assigned to a
primary DES (n ¼ 2,361) or PTA (n ¼ 238). Acute PTA failure occurred in 120 patients
who underwent secondary randomization to DES (n ¼ 61) or BMS (n ¼ 59). A second
single study enrolled 787 patients to DES treatment. Both the primary DES group and the
provisional DES group had statistically signiﬁcant superior patency rates (74.8% and 83.4%,
respectively) than their respective controls. Event-free survival and clinical beneﬁt were also
signiﬁcantly better in the DES group. Dake and colleagues conclude that long-term DES is
safer and clinically superior to PTA and provisional BMS for femoropopliteal disease.INTERVENTIONAL CARDIOLOGYHigh Platelet Reactivity in Peripheral Procedures 2428
Stavros Spiliopoulos, Georgios Pastromas, Konstantinos Katsanos, Panagiotis Kitrou,
Dimitrios Karnabatidis, Dimitrios Siablis
Spiliopoulos and colleagues evaluated the effects of high platelet reactivity in patients
undergoing infrainguinal angioplasty or stenting. Primary endpoint was 1-year clinical event
rate (composite endpoint of death, major stroke, major amputation, target vessel
revascularization, and bypass) and the estimation of the optimal value to predict clinical
outcome based on P2Y12 reaction unit (PRU) divided into quartiles. For the 100 patients
enrolled, the 1-year cumulative event rate was 4% in the ﬁrst quartile and 84% in the fourth
quartiles of PRU. The optimal cut-off value for the composite endpoint was PRU 234, with
a sensitivity and speciﬁcity of 92.1% and 84.2%, respectively. High platelet reactivity (PRU
234) was also the only independent predictor for an increased number of adverse events.
The study showed that high on-treatment platelet reactivity is associated with markedly
increased adverse clinical events in patients undergoing peripheral endovascular procedures.(continued on page A-15)
JUNE 18, 2013 (continued) A-15CARDIAC RESYNCHRONIZATIONElectrocardiographic Mapping Predicts CRT Response 2435Sylvain Ploux, Joost Lumens, Zachary Whinnett, Michel Montaudon, Maria Strom, Charu Ramanathan,
Nicolas Derval, Adlane Zemmoura, Arnaud Denis, Maxime De Guillebon, Ashok Shah, Mélèze Hocini,
Pierre Jaïs, Philippe Ritter, Michel Haïssaguerre, Bruce L Wilkoff, Pierre Bordachar
This study investigates whether 3D electrocardiographic activation mapping (ECM) is useful
in predicting response to cardiac resynchronization therapy (CRT). ECM was performed in
33 consecutive CRT candidates (QRS 120 mg), 18 with left bundle-branch block (LBBB)
and 15 with nonspeciﬁc intraventricular conduction disturbance (NICD). A total of 3 indices
of electric dyssynchrony were derived, including right and left ventricular total activation time
and ventricular electrical uncoupling (VEA). Results revealed that the right ventricular total
activation time was similar in all patients but left ventricular total activation time and
ventricular electrical uncoupling were longer on average in LBBB patients as compared to
NICD. The total response rate to CRT was 64% with NICD patients accounting for only 5
of 21 responders. The left ventricular total activation time was least predictive followed by
QRS duration >145 mg, while LBBB presence and VEA were most predictive. A VEA >50
ms identiﬁed CRT responders with a positive prediction value of 90% and a negative
predictive value of 82%. Electrocardiographic mapping did not enhance the ability to predict
a clinical response in LBBB patients. However, in patients with NICD, the ECM predicted
a clinical response in 3 of 5 patients and clinical nonresponse in 9 of 9 patients.
Editorial Comment: Mitchell N. Faddis, p. 2444CARDIAC IMAGINGStandard Versus Myocardial Contrast Stress Imaging for Outcome 2446
Thomas R. Porter, Lynette M. Smith, Juefei Wu, Deepak Thomas, John T. Haas, Daniel H. Mathers,
Eric Williams, Joan Olson, Kevin Nalty, Roberta Hess, Stacey Therrien, Feng Xie
This paper reports on the clinical outcome of patients after 2 different stress imaging
approaches: real time myocardial contrast echocardiography (RTMCE) versus conventional
stress echocardiography (CSE), using pharmacological or exercise stress. An abnormal
RTMCE was more frequently observed (p < 0.001) and more frequently resulted in
revascularization (p ¼ 0.004) than an abnormal CSE. Resting wall motion abnormalities
were more frequently seen with RTMCE and were an independent predictor of
death/nonfatal myocardial infarction (p ¼ 0.005) for RTMCE, but not CSE. Porter and
colleagues conclude that perfusion imaging with RTMCE improves the detection of coronary
artery disease and identiﬁes those more likely to undergo revascularization.(continued on page A-16)
JUNE 18, 2013 (continued) A-16HYPERTROPHIC CARDIOMYOPATHYBNP and Survival in Hypertrophic Cardiomyopathy 2456
Jeffrey B. Geske, Paul M. McKie, Steve R. Ommen, Paul Sorajja
This study evaluates the prognostic ability of B-type natriuretic peptide (BNP) in patients
with hypertrophic cardiomyopathy (HCM). A total of 772 patients with HCM had BNP
levels as well as echocardiogram, cardiopulmonary exercise, and clinical evaluation. A 3-year
survival by tertile was 99.2% (BNP 98 pg/ml), 94.8% (BNP >98 to <298 pg/ml), and
89.9% (BNP 298 pg/ml). Compared to patients in the ﬁrst tertile, the hazard ratios for
death in the second and third tertile were 4.88 (p ¼ 0.006) and 6.98 (p ¼ 0.0003),
respectively. BNP levels were related to New York Heart Association functional status, the
subsequent need for septal reduction therapy, and were a predictor of survival even in patients
without resting obstruction. Geske and colleagues conclude the BNP is an independent
predictor of morbidity and mortality in patients with HCM.HYPERTENSIONResistant Hypertension in Chronic Kidney Disease 2461
Luca De Nicola, Francis B. Gabbai, Rajiv Agarwal, Paolo Chiodini, Silvio Borrelli, Vincenzo Bellizzi,
Felice Nappi, Giuseppe Conte, Roberto Minutolo
This study evaluates the prevalence and prognosis of true resistant hypertension in patients
with chronic kidney disease (CKD) (not on dialysis). A total of 436 patients with CKD
underwent 24-h ambulatory blood pressure monitoring and where divided into 4 groups:
controls, pseudoresistance, sustained hypertension, and true resistance. A total of 23% of
patients were true resistance, 7.1% were pseudoresistant, and 49.9% were sustained
hypertension. Over a 57-month follow-up, there were 109 cardiovascular (CV) events and
165 renal events. Compared to controls, CV risk (hazard ratio) was 1.24, 1.11, and 1.98, for
pseudoresistance, sustained hypertension, and true resistance, respectively. De Nicola and
colleagues conclude that true resistance carries the highest cardiovascular risk, while sustained
hypertension predicts renal outcomes and pseudoresistance is not associated with increased
cardiorenal risk.
Editorial Comment: Larry A. Weinrauch, Akshay S. Desai, Hicham Skali, John A. D’Elia,
p. 2468
